Bank of America raised its peak sales forecast for Johnson & Johnson's oral psoriasis drug Icotyde to $4.5 billion, up from $2.4 billion, reflecting increased market share assumptions and a sector rerating favoring defensive stocks. The broker projects $70 million in sales for Q3 2026 and $220 million for the full year, aligning with consensus estimates. Despite limited prescription data, the firm maintained overall 2026 revenue forecasts at $25.5 billion with 6% growth, factoring in recent acquisitions and collaborations that increase R&D expenses. Investors should watch upcoming earnings for updates on Icotyde's launch and other product developments.
Johnson & Johnson shares are trading at USD 267.12 on Pluang as of September 30, 2026, 02:21 WIB, down 1.77% for the day. The stock's market cap stands at $655.37 billion, reflecting its significant presence in the health sector. Despite the recent downgrade in price, investors show a high sell activity of 94% on Pluang, indicating cautious sentiment around the stock amid its evolving product pipeline.
New Phase 3 PROTEUS substudy results show that adding apalutamide plus androgen deprivation therapy (ADT) before and after surgery reduces the risk of prostate cancer recurrence or death by 62% compared to surgery alone in high-risk localized or loca...
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
More than 200 companies are actively developing over 240 Alzheimer's disease therapies, with around 20 drugs in late-stage trials and many others in earlier phases. Key players include Eli Lilly, Biogen, Johnson & Johnson, and Eisai, focusing on inno...
